Literature DB >> 8564399

Comparative molecular field analysis of selective A3 adenosine receptor agonists.

S M Siddiqi1, R A Pearlstein, L H Sanders, K A Jacobson.   

Abstract

A series of 48 N6-benzyladenosine 5'-uronamide derivatives has been described recently as moderately selective A3 adenosine receptor agonists of nanomolar potency (Gallo-Rodriguez, C. et al. J. Med. Chem. 1994, 37, 636). Quantitative structure activity relationships in this series, including some novel derivatives, have been investigated using a Comparative Molecular Field Analysis (CoMFA), with emphasis on the N6-substituent. The resulting three dimensional pharmacophore model defines the steric and electronic factors which modulate in vitro affinities in binding to rat brain A3 adenosine receptors. The model indicates a positive correlation of affinity with the steric characteristics of the compounds (major factor), particularly toward the 3-position of the benzyl ring of N6-benzyl NECA, and a weak correlation with the electrostatic effects of the N6-substituent. A comparison of active and inactive compounds using volume maps showed that bulk at the 3-position of the benzyl ring of the molecule is conducive to high affinity at A3 receptors, while steric bulk at other positions of the benzyl ring leads to poor binding. t-Boc-amino acid conjugates of a 3-aminobenzyl derivative were synthesized to probe the steric and hydrophobic limitations at that position. We have discovered a subregion of the N6-benzyl binding pocket occupied by a 3-(L-prolylamino) group that is sterically disallowed at A3 receptors and allowed in A1 and A2a receptors. 6-N-Phenylhydrazino and 6-O-phenylhydroxylamino derivatives, incorporating major changes in electrostatic character of the ligand proximal to the purine, were predicted by the CoMFA model to have high A3 affinity. Such analogs were synthesized and found to be well tolerated at the A3 receptor binding site.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8564399      PMCID: PMC5549266          DOI: 10.1016/0968-0896(95)00116-x

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  24 in total

1.  Mapping the N6-region of the adenosine A1 receptor with computer graphics.

Authors:  P J Van Galen; F J Leusen; A P IJzerman; W Soudijn
Journal:  Eur J Pharmacol       Date:  1989-03-07       Impact factor: 4.432

2.  Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.

Authors:  C Gallo-Rodriguez; X D Ji; N Melman; B D Siegman; L H Sanders; J Orlina; B Fischer; Q Pu; M E Olah; P J van Galen
Journal:  J Med Chem       Date:  1994-03-04       Impact factor: 7.446

3.  Characterization of adenosine receptors in rat brain by (-)[3H]N6-phenylisopropyladenosine.

Authors:  U Schwabe; T Trost
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-09       Impact factor: 3.000

4.  125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor.

Authors:  M E Olah; C Gallo-Rodriguez; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1994-05       Impact factor: 4.436

5.  Molecular cloning and characterization of the human A3 adenosine receptor.

Authors:  C A Salvatore; M A Jacobson; H E Taylor; J Linden; R G Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

6.  Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution.

Authors:  J Linden; H E Taylor; A S Robeva; A L Tucker; J H Stehle; S A Rivkees; J S Fink; S M Reppert
Journal:  Mol Pharmacol       Date:  1993-09       Impact factor: 4.436

7.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.

Authors:  Q Y Zhou; C Li; M E Olah; R A Johnson; G L Stiles; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart.

Authors:  G S Liu; S C Richards; R A Olsson; K Mullane; R S Walsh; J M Downey
Journal:  Cardiovasc Res       Date:  1994-07       Impact factor: 10.787

Review 9.  Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.

Authors:  K A Jacobson; P J van Galen; M Williams
Journal:  J Med Chem       Date:  1992-02-07       Impact factor: 7.446

Review 10.  Adenosine A1 and A2 receptors: structure--function relationships.

Authors:  P J van Galen; G L Stiles; G Michaels; K A Jacobson
Journal:  Med Res Rev       Date:  1992-09       Impact factor: 12.944

View more
  9 in total

1.  Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands.

Authors:  Stefano Costanzi; Irina G Tikhonova; T Kendall Harden; Kenneth A Jacobson
Journal:  J Comput Aided Mol Des       Date:  2008-05-16       Impact factor: 3.686

2.  Molecular modeling of the intestinal bile acid carrier: a comparative molecular field analysis study.

Authors:  P W Swaan; F C Szoka; S Oie
Journal:  J Comput Aided Mol Des       Date:  1997-11       Impact factor: 3.686

3.  A3-adenosine receptors: design of selective ligands and therapeutic prospects.

Authors:  Kenneth A Jacobson; Hea O Kim; Suhaib M Siddiqi; Mark E Olah; Gary L Stiles; Dag K J E von Lubitz
Journal:  Drugs Future       Date:  1995-07       Impact factor: 0.148

4.  A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists.

Authors:  K A Jacobson; R Xie; L Young; L Chang; B T Liang
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

5.  N6-Substituted 5'-N-Methylcarbamoyl-4'-selenoadenosines as Potent and Selective A3 Adenosine Receptor Agonists with Unusual Sugar Puckering and Nucleobase Orientation.

Authors:  Jinha Yu; Long Xuan Zhao; Jongmi Park; Hyuk Woo Lee; Pramod K Sahu; Minghua Cui; Steven M Moss; Eva Hammes; Eugene Warnick; Zhan-Guo Gao; Minsoo Noh; Sun Choi; Hee-Chul Ahn; Jungwon Choi; Kenneth A Jacobson; Lak Shin Jeong
Journal:  J Med Chem       Date:  2017-04-19       Impact factor: 7.446

Review 6.  Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).

Authors:  Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2009-04-30       Impact factor: 4.774

7.  Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists.

Authors:  K A Jacobson; X Ji; A H Li; N Melman; M A Siddiqui; K J Shin; V E Marquez; R G Ravi
Journal:  J Med Chem       Date:  2000-06-01       Impact factor: 7.446

8.  Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.

Authors:  P G Baraldi; B Cacciari; M J Pineda de Las Infantas; R Romagnoli; G Spalluto; R Volpini; S Costanzi; S Vittori; G Cristalli; N Melman; K S Park; X D Ji; K A Jacobson
Journal:  J Med Chem       Date:  1998-08-13       Impact factor: 8.039

Review 9.  An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs.

Authors:  Kenneth Lundstrom
Journal:  Methods Mol Biol       Date:  2009
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.